Asterias Biotherapeutics (AST) Receives New Coverage from Analysts at B. Riley

Analysts at B. Riley assumed coverage on shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) in a report issued on Thursday, MarketBeat.com reports. The brokerage set a “buy” rating and a $6.00 price target on the biotechnology company’s stock. B. Riley’s price target points to a potential upside of 172.73% from the company’s current price.

Other equities research analysts also recently issued research reports about the stock. HC Wainwright reaffirmed a “buy” rating on shares of Asterias Biotherapeutics in a research note on Wednesday, November 22nd. Zacks Investment Research raised shares of Asterias Biotherapeutics from a “hold” rating to a “buy” rating and set a $2.75 target price for the company in a research note on Wednesday, October 25th. Two analysts have rated the stock with a sell rating and four have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and a consensus price target of $8.35.

Shares of Asterias Biotherapeutics (NYSEAMERICAN:AST) opened at $2.20 on Thursday. Asterias Biotherapeutics has a 12 month low of $1.95 and a 12 month high of $4.30. The company has a market cap of $119.13, a P/E ratio of -3.38 and a beta of 1.07.

Several institutional investors have recently added to or reduced their stakes in the company. Virtu Financial LLC boosted its holdings in shares of Asterias Biotherapeutics by 387.0% in the fourth quarter. Virtu Financial LLC now owns 71,588 shares of the biotechnology company’s stock valued at $161,000 after buying an additional 56,888 shares during the period. Deutsche Bank AG boosted its holdings in shares of Asterias Biotherapeutics by 110.5% in the fourth quarter. Deutsche Bank AG now owns 66,180 shares of the biotechnology company’s stock valued at $148,000 after buying an additional 34,739 shares during the period. Finally, Millennium Management LLC acquired a new position in shares of Asterias Biotherapeutics in the fourth quarter valued at approximately $132,000.

WARNING: “Asterias Biotherapeutics (AST) Receives New Coverage from Analysts at B. Riley” was originally published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The original version of this article can be read at https://www.dispatchtribunal.com/2018/02/24/asterias-biotherapeutics-ast-receives-new-coverage-from-analysts-at-b-riley.html.

About Asterias Biotherapeutics

Asterias Biotherapeutics, Inc is a biotechnology company. The Company is engaged in developing and commercializing therapies in the fields of cell therapy and regenerative medicine. The Company has over two technology platforms. The first is an immunotherapy platform to teach cancer patients’ immune systems to attack their tumors.

Receive News & Ratings for Asterias Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Asterias Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply